Strategic development partership sought

In cooperation with the contract research organization Evotec AG our company develops small molecule-based first-in-class drugs targeting the (pro)renin receptor with respect to the following indications:

(1) end-organ damage caused by diabetes and hypertension (diabetic nephropathy, diabetic retinopathy, heart failure)

(2) multiple oncological diseases (colorectal cancer, hepatocellular carcinoma, melanoma)

Currently, we are in the (pre)lead-to-preclinical development candidate (PDC) stage.

Several in vivo proof-of-concept experiments regarding both indications have already been successfully performed.

We are looking for a strategic development partnership in the field of diabetes and/ or oncology.

You may contact us on info(at)ccrp-therapeutics.com.

Alternatively you can also use this form, please fill out the fields marked with * to contact you back.